BioSpace News Archive

Alvotech announced that it has entered into an exclusive agreement with Advanz Pharma, for the commercialization of AVT23, a proposed biosimilar to Xolair®.

Bioweg and Ginkgo Bioworks announced a collaboration to optimize the production of bacterial cellulose and to produce novel variants of cellulose with improved performance to serve a variety of end markets.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced results from the AcQForce Flutter Study “AcQForce Flutter: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter”.

Blue Lake Biotechnology, Inc. announced that the company’s founder and CEO, Biao He , PhD, will be presenting at the 2023 BIO CEO and Investor Conference in New York, today at 4:30pm EST. During the presentation, Dr. He will share preliminary results from the Phase 1 trial (NCT04954287) of the CVXGA1 COVID vaccine.

Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Endogena Therapeutics Inc. announced today that the US Food and Drug Administration (FDA) has designated the investigation of EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development program.

Opthea Limited announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at SVB Leerink’s Global Biopharma Conference being held virtually on February 14-16, 2023.

NanoString Technologies, Inc. today announced an update to the technology roadmap for the CosMx™ Spatial Molecular Imager (SMI) that will be presented at the 2023 Advances in Genome Biology and Technology General Meeting in Hollywood, FL.

Slingshot Biosciences today announced the closing of $11 million in a Series A3 financing.